Acorda Therapeutics Presents Positive Data from Preclinical Studies of Neuregulins in Cardiac Function
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented data on the company’s neuregulin molecule GGF2 demonstrating improved cardiac function in preclinical models of heart failure. The data also indicated that GGF2 provided more benefit than other neuregulin fragments that were also tested. In preclinical testing, neuregulins have shown the potential to reduce and even reverse dysfunction of congestive heart failure by strengthening and protecting heart muscle cells. Data on GGF2 were presented on July 29 at the Basic Cardiovascular Sciences Conference in Keystone, CO.